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Autoantibodies against the RhoGTPase-activating protein 26 (ARHGAP26) were
originally identified in the context of subacute autoimmune cerebellar ataxia. Further
studies identified a wider clinical spectrum including psychotic, affective, and cognitive
symptoms. Only a few patients reported so far had evidence of a tumor association.
A prospective analysis between January 2015 and December 2017 at the Dept. of
Neurology at Charité—Universitätsmedizin Berlin identified 14 patients with ARHGAP26
autoantibodies on a cell-based assay, of which three patients had additional brain
immunohistochemistry staining of cerebellar molecular layer and Purkinje cells, who were
therefore considered antibody-positive. In all three patients, ARHGAP26 autoantibodies
were associated with tumors. In two patients, an isolated cognitive impairment without
additional neurological deficits was observed. These cases thus further extend the
clinical spectrum associated with ARHGAP26 autoantibodies and strengthen a potential
paraneoplastic context.
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INTRODUCTION
Autoantibodies against the RhoGTPase-activating protein 26 (ARHGAP26) were originally
identified in patients with subacute autoimmune cerebellar ataxia (ACA). The first patient was
described in 2010 and presented with limb and gait ataxia, dysarthria and diplopia developing over
a period of 2 weeks, followed by hyperekplexia, depression, restlessness, and anxiety. Further tests
revealed normal CSF cell count, but intrathecal IgG synthesis and subsequent cerebellar atrophy
on MRI. No tumor was detected (1). Two more patients with ARHGAP26 autoantibodies and
cerebellar ataxia were reported 3 years later (2). In one of these patients, antibody detection lead
to the discovery of ovarian cancer, suggesting ARHGAP26 autoantibodies as a potential marker
of a paraneoplastic neurological syndrome (PNS). The other reported patient had weight loss, but
no further tumor workup was performed. In an additional case, ARHGAP26 antibodies were not
only associated with cerebellar ataxia, but also with cognitive and affective symptoms, indicating
a broader clinical spectrum (3). This notion was further supported by the report of a fifth case
with recurrent psychotic episodes, but no signs of cerebellar ataxia (4). Recently, two more cases
have been described including one with cerebellar ataxia and a history of both breast cancer and
melanoma and a second case with cerebellar ataxia, tremor, myoclonus, depression, and mild
cognitive deficits (5).
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In summary, ARHGAP26 autoantibodies were primarily
reported in patients with cerebellar ataxia, but have also been
associated with additional clinical features such as psychotic
symptoms, depression, and cognitive decline. A tumor was
detected in some of these patients, suggesting a potential
paraneoplastic etiology.
Here, we report three new cases with predominant cognitive
impairment and associated malignancy, further extending the
clinical spectrum associated with ARHGAP26 autoantibodies
and strengthening their potential paraneoplastic context.
METHODS
Patients
Patients with a suspected autoimmune-mediated brain
disorder seen at the Department of Neurology at Charité—
Universitätsmedizin Berlin and 1,055 additional tumor patients
were prospectively screened for neuronal autoantibodies
between January 2015 and December 2017. Tumor patients
had a confirmed diagnosis of melanoma, prostate, lung, breast,
gastric/esophageal, or colon cancers, leukemia, or lymphoma
and were recruited at the corresponding departments. Patient
charts were retrospectively reviewed. The study was approved
by the ethics committee of Charité—Universitätsmedizin Berlin
and all patients gave written informed consent for publication.
Antibody Detection
ARHGAP26 autoantibodies were detected by cell-based
assay (CBA) and immunohistochemistry. Patients were only
considered antibody-positive if both assays were positive.
The CBA used fixed human recombinant HEK293-cells
expressing ARHGAP26 (Euroimmun AG, Lübeck, Germany).
For immunohistochemistry, cryosections of brain tissue (rat
hippocampus, rat cerebellum, monkey cerebellum, Euroimmun
AG) were incubated with patient serum/CSF using indirect
immunofluorescence. The previously described IgG cerebellar
staining pattern of the molecular layer and Purkinje cells (PC)
was considered positive on immunohistochemistry (1).
CBA revealed 14 ARHGAP26-positive patients with
serum titers between 1:10 and 1:10,000. Of those, samples
from three patients showed typical cerebellar staining
on immunohistochemistry and were therefore considered
antibody-positive in this study.
Neuropsychological Assessment and
Cerebral MRI
Detailed cognitive assessment was performed using
neuropsychological tests evaluating working memory, verbal,
and visuospatial long-term memory, attention, language,
executive functions, and premorbid intelligence level. In case 2,
the Montreal Cognitive Assessment (MOCA) was performed,
including tests for short-term memory, visuospatial abilities,
executive function, attention, and language (6). In case 1, MRI
data was acquired on a 1.5T Symphony Vision scanner (Siemens,




This 84 year-old patient presented with progressive
anterograde amnesia developing within a few weeks,
followed by Broca’s aphasia, loss of appetite, weight loss,
intermittent hyponatremia, gait ataxia, and emotional instability.
Neurological examination showed vertical and horizontal
saccadic eye movements with occasional ocular flutter,
generalized muscular atrophy, brisk tendon reflexes, gait
ataxia, marked dysdiadochokinesia, and impaired fine-motor
skills. Detailed neuropsychological testing revealed mild
cognitive impairment with deficits of attention, word fluency,
working, and anterograde verbal memory. Cerebral MRI showed
marked generalized atrophy and signs of microangiopathy
(Figures 1A,B). Basic CSF studies were unremarkable, protein
14-3-3 was negative. The patient had a medical history of
monoclonal gammopathy (MGUS) (IgM-lambda) and multiple
cardiovascular risk factors including arterial hypertension
(AHT), coronary artery disease (CAD) and minor posterior
circulation strokes without persistent neurological deficits.
Serological testing revealed ARHGAP26 autoantibodies with a
1:1,000 titer and a typical staining pattern on brain tissue, i.e.,
IgG staining of cerebellar molecular layer and PCs.
The patient was started on oral methylprednisone 500
mg/d for 3 days, followed by 40 mg/d for 4 weeks and
subsequent weekly reduction by 10mg. In light of a possible
PNS, further diagnostic workup was recommended. Follow-
up studies revealed a decrease in serum titer to 1:32 with
no antibodies detected in CSF. Again, CSF basic studies were
unremarkable, but CSF-specific oligoclonal bands (OCBs) were
positive. Phospho-TAU/TAU, beta-amyloid and beta-amyloid
ratio were unremarkable. Cerebral MRI remained unchanged
and a whole-body PET-CT revealed no tumor signs. The
patient received four cycles of plasmapheresis with mild
improvements of short-term memory and was discharged for
rehabilitation.
Three months later, the patient presented with agitation and
depression. At this point, serum testing showed an ARHGAP26
antibody titer of 1:100 and the previously documented MGUS
(IgM-lambda). Further hematologic work-up revealed a B-cell
lymphoma, for which the patient was started on obinutuzumab
and chlorambucil.
Case 2
This 73-year-old patient with prostate cancer presented with
slowly progressive memory decline over the last years, mainly
having trouble remembering new names and appointments.
He had been diagnosed with prostate cancer 10 years before
and hepatic metastases were detected a few months prior to
presentation. He had a history of asthma and migraine, but
had been without symptoms for over 20 years. At the time of
presentation, his prostate cancer was treated with docetaxel.
His neurological examination was unremarkable, except
for mild tandem gait imbalance. The Montreal Cognitive
Assessment (MOCA) revealed mild cognitive impairment with
22/30 points (normal ≥26) with deficits in language, abstraction,
Frontiers in Neurology | www.frontiersin.org 2 August 2018 | Volume 9 | Article 656
Bartels et al. ARHGAP26 Autoantibodies and Cognitive Impairment
FIGURE 1 | (A, B) Cerebral MRI of case 1. (A) Coronal T2 TIRM image and (B) Contrast-enhanced MPGRAGE image showing whole brain atrophy apparent in the
frontal and parietal cortex as well as in the insular region with proportional atrophy of the hippocampus and the cerebellum as well as signs of microangiopathy.
(C–F) Immunohistochemistry, representative images of case 2. All images taken at 200x magnification. (C) Cell-based assay with recombinant ARHGAP26-expressing
HEK293-cells, 1:100 dilution, showing binding of patient serum IgG to ARHGAP26-expressing cells. (D) Empty-vector control cells after incubation with patient serum
(1:100 dilution) demonstrates no binding of patient IgG. (E) Cerebellum monkey, 1:100 dilution with patient serum IgG, showing staining pattern of molecular layer
(ML) and Purkinje cell layer (PCL). (F) Cerebellum rat, 1:100 dilution, Note patient serum IgG binding to molecular layer, Purkinje cell layer (PCL), but not white matter
(WM). ML, molecular layer; PCL, Purkinje cell layer; GL, granular layer; WM, white matter.
verbal memory, and orientation. ARHGAP26 antibodies were
detected in serum with a CBA (titer 1:3,200) (Figures 1C,D).
Immunohistochemistry identified the typical cerebellar staining
of the molecular layer and PCs (dilution 1:1,000) (Figures 1E,F).
Interestingly, rat hippocampal staining showed a fine granular-
to-smooth pattern (1:320). 6 month later, immunohistochemistry
remained highly indicative of ARHGAP26 (1:3,200), while
the CBA titer increased to 1:10,000. The patient received no
immunosuppressive therapy and died a few months later of
metastasized prostate cancer.
Case 3
This 77-year-old man with gastric adenocarcinoma und
lung metastases showed cognitive impairment in a detailed
neuropsychological work-up. He was diagnosed with
gastric carcinoma following abdominal pain 2 years prior
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to presentation. The patient, a smoker with 30 pack-years, had
a history of CAD, AHT, peripheral artery disease, and chronic
obstructive pulmonary disease. Staging revealed a pulmonary
nodule that was consistent with a distant metastasis of the
gastric adenocarcinoma on biopsy. The patient was started on
chemotherapy with four cycles of FLOT regimen (fluorouracil,
leucovorin, oxaliplatin, and docetaxel), followed by gastric
resection and radiotherapy of the lung metastasis with additional
four cycles of adjuvant FLOT chemotherapy.
At the time of presentation, there was no evidence of
local carcinoma recurrence. The pulmonary nodule remained
stable. Neurological examination was unremarkable. Cognitive
testing showed deficits in short-term memory, attention, and
executive function. Serum testing revealed autoantibodies against
ARHGAP26 on CBA (1:100) and immunohistochemistry (1:100).
Table 1 summarizes clinical and diagnostic features of all
previously reported ARHGAP26-positive patients including the
cases above.
DISCUSSION
We here describe three new ARHGAP26-positive cases with
isolated cognitive impairment in two patients and a tumor
association in all three cases, suggesting a broader clinical
spectrum and highlighting the importance to screen antibody-
positive patients for malignancies.
The previously described clinical spectrum associated with
ARHGAP26 autoantibodies includes cerebellar ataxia, but also
psychotic, affective and cognitive symptoms (1–5). In line with
the initial context of cerebellar ataxia, immunohistochemistry
revealed binding to cerebellar molecular layer and PC cytoplasm
and membrane (1). While a pathogenic role of ARHGAP26
autoantibodies remains unknown, tissue staining would be
consistent with a clinical effect of pure cerebellar syndrome.
However, other associated clinical symptoms such as depression,
psychotic behavior and cognitive deficits would be more difficult
to explain. Here, we observed predominant cognitive impairment
in three ARHGAP26-positive patients - with in fact isolated
cognitive deficits without other neurological symptoms in two
of the patients. Affected cognitive domains included attention,
short-term and workingmemory, verbal memory, semantic word
fluency, and executive function.
One possible explanation for cognitive deficits in
ARHGAP26-positive patients is that autoantibodies not
only bind to cerebellum, but also other brain structures
such as limbic regions including the hippocampus. Indeed,
ARHGAP26 was found to be expressed in a subset of
hippocampal neurons (4, 7). In a previous ARHGAP26-
positive case with isolated psychiatric symptoms the authors
concluded that the lack of cerebellar symptoms in that patient
suggests other brain regions to be involved (4). Furthermore,
they pointed out that in other antibody-associated neurological
disorders, a wide clinical spectrum of one single antibody
(e.g., anti-Hu, anti-AQ4) is common, presumably due to
widespread expression of the antigen. Interestingly, in our
case 2, immunohistochemistry revealed hippocampal staining,
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suggesting a potential autoimmune response to the limbic
system, although the presence of another, yet undefined antibody
cannot be excluded.
Alternatively, cognitive symptoms could directly be mediated
by cerebellar dysfunction, as conceptualized by the cerebellar
cognitive–affective syndrome (Schmahmann’s syndrome) (8–
10). Schmahmann’s syndrome occurs in patients with isolated
cerebellar disease and includes deficits of attention, working
and verbal memory, visuo-spatial cognition, executive function,
language as well as behavior and affect (11). It is therefore
well-suited to explain the cognitive and affective symptoms
in patients with ARHGAP26 antibodies. However, isolated
cognitive deficits in Schmahmann’s syndrome have not been
reported so far. Associated anatomical regions include large
bilateral or pancerebellar damage (8). Due to the lack of post-
mortem studies in ARHGAP26-positive patients, the targeted
cerebellar regions are unknown, but MRI studies revealed
generalized cerebellar atrophy. Therefore, it seems plausible that
isolated cognitive dysfunction could be part of a cerebellar
cognitive-affective syndrome in ARHGAP26-positive patients
(3).
An underlying tumor was only found in two of the seven
previously reported cases (2, 5), whereas all three of the here
described patients had a cancer diagnosis before or revealed on
further work-up. Autoantibodies targeting intracellular antigens
are frequently associated with underlying malignancy and can
precede cancer diagnosis by up to 15 months (12, 13). Therefore,
delayed tumor detection in previous cases cannot be excluded.
Indeed, repeated tumor screening in case 1 led to the diagnosis of
B-cell lymphoma 12 months after initial presentation. With these
three new cases, now 50% of all reported ARHGAP26-positive
patients had a tumor-association, emphasizing the importance
to screen for underlying malignancy. Interestingly, ARHGAP26
was found to be expressed in most samples of prostate cancer,
suggesting a possible trigger in case 2 (7).
Immunosuppressive therapy was only administered in one
patient. Here, mild improvement of short-term memory was
observed after steroids and plasmapheresis, even before tumor
detection and treatment. This suggests a potential benefit of
immunosuppressive therapy. Tumor treatment was initiated
or continued in all patients. While one patient died of his
prostate cancer, long-term outcome of the other patients
remains to be seen. Previous cases reported little effect of
immunosuppressive therapy at best, ideally stabilizing patients
with the existing deficits (5). Long-term clinical follow-up and
evaluation of patient outcome after immunosuppressive
and tumor therapy should be addressed in future
studies.
We considered patients antibody-positive only when being
positive in both assays, CBA and immunohistochemistry on
brain sections. Of the 11 patients that were positive on CBA only
(i.e., without the corresponding immunohistochemistry pattern),
three underwent neuropsychological assessment. Interestingly,
two of these patients also had isolated cognitive impairment. It
is unclear whether in these cases the CBA is more sensitive than
immunohistochemistry, similar to assays with other antibodies
such as against the NMDA receptor. Alternatively, antibodies
may bind to an epitope that is present only on recombinantly
expressed antigens in the CBA or which is lost on brain sections,
e.g., due to tissue processing including fixation. Further clinical
correlations with more patients are required to disentangle the
significance of isolated positive CBAs.
In summary, we here describe three new cases with
ARHGAP26 autoantibodies with tumor association that
presented with predominant cognitive impairment. This allows
for the following conclusions for clinical practice: (1) The
spectrum of ARHGAP26-associated symptoms is broader
than initially expected and also includes isolated cognitive
impairment; (2) A positive ARHGAP26 antibody-test should
prompt the search for an underlying malignancy; and (3)
ARHGAP26-mediated autoimmune encephalopathy is a
potential, yet rare differential diagnosis in patients with cognitive
impairment.
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